Key Highlights
- Loss was USD 0.25 per share against an estimated USD 0.18 loss, and Revenue of USD 18.42 million edged past.
- Third quarter revenue was the best in company history, and year-to-date revenue growth exceeded 11%.
- Gross Margin rose to 58.8% from 58.4%, and adjusted EBITDA is up more than 30% year to date.
- Full-year revenue guidance of USD 72 to 75 million was reiterated, with a myositis offering scheduled for early 2027.
Exagen (NASDAQ:XGN), an autoimmune testing company, reported third quarter 2026 revenue of USD 18.4 million, which management described as the best third quarter in company history. Revenue narrowly exceeded the USD 18.34 million estimate. Loss per share of USD 0.25 was wider than the USD 0.18 estimated loss.
Year to date, revenue has grown more than 11%, which management said contributed to an adjusted EBITDA improvement of over 30%. Test Volume is up 8% year to date, and the company is approaching 1.3 million AVISE CTD tests performed since launch.
Gross margin was 58.8% against 58.4% a year earlier. Cost of revenue rose USD 0.4 million, or 5.7%. Selling, general and administrative expenses rose USD 1.4 million, or 12.1%, and Research and Development expenses rose USD 0.1 million, or 5.4%. For the nine months, cost of revenue increased USD 2.1 million, or 10.1%.
The lead product represented 90% of revenue for the nine months, compared with 89% a year earlier. Pharma services revenue rose about USD 1.0 million to USD 2.2 million for the nine months.
Guidance and Cash
Management reiterated full-year revenue guidance of USD 72 million to USD 75 million. For the nine months, the company incurred a net loss of USD 13.5 million, against USD 15.3 million a year earlier, and it states it expects additional losses in future periods. The accumulated Deficit was USD 327.8 million, and cash and cash equivalents were USD 28.1 million.
Services and Product Pipeline
For partners in Phase 1 through Phase 3 trials, in vitro diagnostic development and biobanking, the company now offers 38 biomarkers, up from 32 last year. In the third quarter, test volume growth was 2%, trailing 12-month revenue per sales territory rose nearly 6% as territories expanded from 42 to 45, and trailing 12-month average selling price reached USD 451 per test, up USD 10. About USD 800,000 was collected from claims older than 360 days. Management targets an average selling price of at least 50% of Medicare reimbursement, or about USD 600 to USD 650 per test, while noting quarterly contribution from revenue cycle work can vary. Adjusted EBITDA loss was USD 1.9 million, equal to the prior-year quarter, and about one third of each incremental revenue dollar has flowed to adjusted EBITDA this year. Management said recoveries on claims more than a year old are more than 2.5 times last year's level as the revenue cycle team uses analytics and artificial intelligence to optimize processes. A myositis testing offering is scheduled to launch in early 2027.
The filing's legal proceedings item states the company may be involved in legal proceedings or claims in the ordinary course of business, and that such matters can adversely affect results through defense and settlement costs.
Items to Follow
Revenue against the guided range, test volume growth, gross margin, selling expense growth and cash use are the figures to follow into the fourth quarter.






Please wait processing your request...